NCT04250922: An ongoing trial by Laminar Pharmaceuticals
This trial is ongoing. It must report results 9 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04250922 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 1, 2019 |
| Completion date | Jan. 15, 2026 |
| Required reporting date | Jan. 15, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |